polycystic liver disease
Conditions
Interventions
experimental group:TAE with Bleomycin hydrochloride + n-butyl cyanoacrylate + iodized oil emulsion
control group:TAE with n-butyl cyanoacrylate + iodized oil emulsion
Sponsors
The First Medical Center, Chinese PLA General Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years; 2. Those who were diagnosed with polycystic liver disease by contrast-enhanced CT or MRI of the abdomen and caused severe clinical symptoms, such as abdominal distension, abdominal pain, dyspnea, etc., who failed conservative treatment; 3. The risk of surgical resection is high or surgery is refused; 4. ECOG-PS score 0-1 points; 5. There are no other contraindications for angiography (such as contrast agent allergy, uncontrolled infection, uncorrectable coagulation disorder, etc.); 6. The subjects voluntarily joined the study, signed the informed consent, and were able to cooperate with the follow-up and complete the research project.
Exclusion criteria
Exclusion criteria: 1. Severe abnormal liver function (ALT/AST>=4ULN, DBIL>=3ULN) 2. Abnormal coagulation function (INR>1.5 or prothrombin time (PT)>ULN+4 seconds), with bleeding tendency or receiving thrombolytic or anticoagulation therapy; 3. Active period of infectious disease; 4. Those with severe heart, lung, kidney, brain and other underlying diseases who cannot tolerate interventional therapy; 5. Menstrual period women wait until the end of the menstrual period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease control rate; | — |
Countries
China
Contacts
Public ContactWang Maoqiang
The First Medical Center, Chinese PLA General Hospital
Outcome results
None listed